LRRK2 and Parkinson disease: The fact that NME1 increases mitochondrial respiration, together with the finding that NME1 protects against α-synuclein and G2019S LRRK2-induced degeneration, is an important proof-of-principle that NME1 may be a promising therapeutic agent for neuroprotection in PD.